We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

By LabMedica International staff writers
Posted on 13 Jun 2025

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. More...

A Knowledge Transfer Partnership (KTP) between Aston University (Birmingham, UK) and BG Research (Kimbolton, UK) will help to further develop technology to rapidly diagnose serious and high-risk infectious diseases. CENOS, developed by BG Research, uses a portable and robust instrument that can deliver fast RT-PCR (Real Time Polymerase Chain Reaction) tests directly from unprocessed samples of blood, swab, saliva, or urine.

The platform is designed for use in remote locations, as it does not require specialist personnel or laboratory equipment and can be easily scaled in the event of an outbreak. PCR tests, used during the COVID-19 pandemic, usually require analysis in a laboratory, taking a day or more to get a result. CENOS can deliver results in around 30 minutes, enabling infected patients to be quickly isolated and treated.

CENOS can also be used for early detection of those infected but without symptoms, helping to minimize transmission and contain outbreaks. The technology is currently being piloted in veterinary settings, testing livestock for avian influenza, foot and mouth disease, Newcastle disease, and African swine fever. The KTP between Aston University and BG Research will take the company’s existing prototype and optimize its design for low-cost and high-volume manufacturing while enhancing key characteristics such as robustness, reliability, and ease of operation, assembly, and servicing.

The research will draw on expertise in the design for manufacture of medical devices from Aston University’s Engineering 4 Health (E4H) Research Centre and use the University’s advanced facilities in prototyping, materials engineering, and manufacturing processes. E4H combines research in all fields of engineering (biomedical, mechanical, chemical, electrical, and computer sciences) with health disciplines to translate innovative and emerging engineering technologies into healthcare.

The KTP will provide BG Research with a clear path towards high-volume manufacture, enabling the company to launch the CENOS instrument commercially, initially for veterinary use but, once the necessary regulations are obtained, for use in human diagnostics worldwide.

“We met with six university teams around the country, but were highly impressed with Aston University and chose them as our KTP partner,100% on merit. The University has the reach, interest, and facilities to help us get to where we need to be,” said Nelson Nazareth, managing director and chief technology officer of BG Research.

“This KTP offers us an opportunity to be involved in something with the potential to have a major impact on managing the progression of infectious diseases in countries where their burdens are most strongly felt,” added Dr. Patrick Geoghegan, senior lecturer in mechatronics and biomedical engineering and a member of the Engineering 4 Health Research Centre (E4H) at Aston University. “We hope it’s the start of a long relationship with BG Research, where we can work together to achieve their goals.”

Related Links:
Aston University
BG Research


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Whole Blood Control
Lyphochek Whole Blood Control
New
See-Saw Rocking Shaker
SH-200D-S-L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Gut microbes may help in recognizing and treating pancreatic cancer (Photo courtesy of Adobe Stock)

Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. Now, a new international collaborative study suggests... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.